CDK1 and acute myeloid leukemia: In comparison with two other approaches to target FLT3-ITD AML using either a FLT3 inhibitor (MLN518) or a CDK1 inhibitor (flavopiridol), OTS514 was significantly more effective in reducing cell viability at a lower IC50 than MLN418 and flavopiridol (Supplementary Figure S9).